|
| |
Enzon PharmaceuticalsWe are a biopharmaceutical company dedicated to the development and commercialization of therapeutics to treat patients with cancer and other life-threatening diseases. Our specialized sales force markets ABELCET®, ONCASPAR®, ADAGEN®, and DEPOCYT® in North America. In addition, we also receive royalties on sales of PEG-INTRON®, marketed by Schering-Plough Corporation, and MACUGEN®, marketed by OSI Pharmaceuticals and Pfizer Inc. Our product-driven strategy includes an extensive drug development program that leverages our proprietary technologies, including a next-generation PEGylation platform that utilizes linkers designed to release compounds at a controlled rate. Internal research and development efforts are complemented with strategic initiatives, such as partnerships designed to broaden our revenue base or provide access to promising new technologies or product development opportunities.
| Contact Details: |
| 685 Route 202/206 |
| Bridgewater |
| New Jersey |
| 08807 |
| United States of America |
| Tel: | (908)541-8600 |
| Fax: | (908)575-9457 |
| Email: | careers@enzon.com |
| WWW: | www.enzon.com/
|
|
Loading...
|
Recent Publications by Enzon Pharmaceuticals: |  |
Marked therapeutic efficacy of a novel polyethylene glycol-SN38 conjugate, EZN-2208, in xenograft models of B-cell non-Hodgkin's lymphoma.
Examination of the clinical utility of SN38... | 2nd October, 2009
| Enzon Pharmaceuticals, Inc., 20 Kingsbridge Road, Piscataway, NJ 08854,
| Haematologica. 2009 Oct;94(10):1456-9.
DOI Direct Link |
A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth.
Hypoxia-inducible factor-1 (HIF-1) is a transcription factor that plays a... | 23rd December, 2008
| Enzon Pharmaceuticals Inc., 20 Kingsbridge Road, Piscataway, NJ 08854,
| Mol Cancer Ther. 2008 Nov;7(11):3598-608. Epub 2008 Oct 30.
DOI Direct Link |
Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers.
CPT-11, also known as irinotecan, is a prodrug that is approved for the... | 29th July, 2008
| Enzon Pharmaceuticals, Inc., 20 Kingsbridge Road, Piscataway, New Jersey
| Bioconjug Chem. 2008 Apr;19(4):849-59. Epub 2008 Mar 28.
DOI Direct Link |
Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model.
PURPOSE: Clinical development of SN38, the active metabolite of... | 21st May, 2008
| Enzon Pharmaceuticals, Inc., Piscataway, New Jersey 08854, USA.
| Clin Cancer Res. 2008 Mar 15;14(6):1888-96.
DOI Direct Link |
Releasable PEGylation of proteins with customized linkers.
Releasable PEGylation employs customized linkers that reversibly tether a... | 6th May, 2008
| Enzon Pharmaceuticals, Inc., 20 Kingsbridge Road, Piscataway, New Jersey
| Adv Drug Deliv Rev. 2008 Jan 3;60(1):29-49. Epub 2007 Aug 16.
DOI Direct Link |
→View more Enzon Pharmaceuticals research publications. |
Press Releases on Enzon Pharmaceuticals:
|
 |
| Santaris Pharma A/S Expands Executive Team, Appoints Chief Medical Officer and Chief Business Officer to Advance Proprietary RNA-targeted Drug Development Programs |
28th October, 2009 |
Santaris Pharma A/S |
HOERSHOLM, Denmark and SAN DIEGO, California, October 28 /PRNewswire/ --
- Industry Expert Mark Wedel, MD, FACP Joins as Vice President and Chief
Medical Officer Responsible for Global
|
| Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment |
26th October, 2009 |
Reportlinker |
-- A focus on "engineered" antibodies
Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment reviews the broad drug development effort that is focused on bringing
|
| Reportlinker Adds Competitor Analysis: PI3K-AKT-mTOR Inhibitors |
16th October, 2009 |
Reportlinker |
-- additional comments with a hyperlink leading to the source of
information.
Index
-- Selective PI3K Inhibitors in Oncology Indications
-- Selective PI3K Inhibitors in
|
| New Collaborations and Breakthrough Advancements in RNA-Based Drug Development Programs Lead Santaris Pharma A/S to Establish US Operations |
16th September, 2009 |
|
HOERSHOLM, Denmark and SAN DIEGO, California, September 16 /PRNewswire/ -- Santaris Pharma A/S, a privately-held biopharmaceutical
company focused on developing RNA-based drugs targeted to disease
|
| Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule |
27th April, 2009 |
Santaris Pharma A/S |
COPENHAGEN, April 27 /PRNewswire/ -- As a testimony to the strength of
Santaris Pharma's efficient Drug Discovery Engine, the Company announced
today the completion of the delivery of six
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 441 times since April 2007, the link to the organisation's website has been followed 55 times Search for more companies in Bridgewater Search for more companies in New Jersey This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Enzon Pharmaceuticals |
